Beam Therapeutics Inc.
BEAM
Updated: 24/09/2026, 11:06:21
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
No summaries found.
- Share price
- $24.37
- Market cap
- $2.51B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- John Evans
- Employees
- 540
- IPO date
- 06/02/2020
- Beta
- 2.226
- Last dividend
- $0.00
- Day range
- $24.22 – $26.24
- 52-week range
- $20.23 – $38.26
- 1-day performance
- -6.02%
- 1-year performance
- 20.46%
- Current drawdown (1Y)
- -36.30%
- CIK
- 0001745999
- CUSIP
- 07373V105
- ISIN
- US07373V1052
- Created
- 07/12/2025, 02:57:47
- Last update
- 24/09/2026, 11:06:21
Track Beam Therapeutics Inc. with an AI analyst
See which prediction-market events move BEAM, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Zacks Investment Research • STOCK • 02/06/2026, 15:10:18
Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 25/05/2026, 15:37:05
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances
MarketBeat • STOCK • 20/05/2026, 16:05:29
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
GlobeNewsWire • STOCK • 18/05/2026, 18:00:00
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
PRNewsWire • STOCK • 13/05/2026, 13:49:00
Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story
Seeking Alpha • STOCK • 13/05/2026, 11:46:02
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
GlobeNewsWire • STOCK • 12/05/2026, 11:30:00
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates
Zacks Investment Research • STOCK • 08/05/2026, 15:11:19
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
GlobeNewsWire • STOCK • 07/05/2026, 09:00:00
3 Biotech Stocks That Could Benefit from the Patent Cliff
MarketBeat • STOCK • 27/04/2026, 09:06:01
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.
The Motley Fool • STOCK • 11/04/2026, 11:20:03
BEAM Eyes Global Expansion of AATD Study After Strong Early Data
Zacks Investment Research • STOCK • 26/03/2026, 13:10:28